Artrya (AYA) H2 2024 earnings summary

Executive summary

• FY24 focused on preparing for global commercialisation, especially in the US, and accelerating rollout in Australia.

• Achieved commercial launch in Australia and established strategic partnerships with major US hospital groups.

• Entered final stages of US FDA 510(k) approval for Salix Coronary Anatomy, with clearance anticipated in H2 FY25.

• First revenues from Australian operations received in Q1 FY25, validating the business model.

• Secured access to the world’s largest CCTA image database for AI-driven research.

Financial highlights

• Reported FY24 net loss of $14.0m, compared to $11.1m loss in FY23.

• Revenue increased to $3.7m from $1.0m year-over-year.

• Cash balance at year-end was $7.1m, down from $20.1m in FY23.

• Net assets decreased to $16.8m from $30.6m year-over-year.

• Basic and diluted EPS were both -17.80 cents, compared to -14.21 cents in FY23.

Outlook and guidance

• Anticipates FDA clearance for Salix Coronary Anatomy in H2 FY25, enabling US commercial launch.

• Plans to expand commercialisation in Australia, US, UK, and other jurisdictions leveraging regulatory approvals.

• Focused on developing and launching additional products, including Salix Coronary Flow.

• Intends to pursue further funding opportunities to support growth and commercialisation.